中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
机构
采集方式
内容类型
发表日期
学科主题
筛选

浏览/检索结果: 共32条，第1-10条 帮助

条数/页： 排序方式：
Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors 期刊论文  OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 233, 页码: 13
作者:  Tang, Qidong;  Peng, Ting;  Hu, Jie;  Zhang, Tao;  Chen, Pengqin
  |  收藏  |  浏览/下载：30/0  |  提交时间：2022/08/16
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文  OAI收割
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun
  |  收藏  |  浏览/下载：69/0  |  提交时间：2021/06/11
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文  OAI收割
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun
  |  收藏  |  浏览/下载：61/0  |  提交时间：2021/06/11
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers 期刊论文  OAI收割
INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8
作者:  Zhu, Yun-ting;  Zhang, Yi-fan;  Jiang, Jin-fang;  Yang, Yong;  Guo, Li-xia
  |  收藏  |  浏览/下载：37/0  |  提交时间：2021/05/24
Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry 期刊论文  OAI收割
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 卷号: 176, 页码: 6
作者:  Liu, Xiaoyun;  Li, Wei;  Zhang, Yifan;  Jian, Yong;  Zhao, Qianyu
  |  收藏  |  浏览/下载：43/0  |  提交时间：2020/07/01
Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein 期刊论文  OAI收割
Acta pharmacologica Sinica, 2018
作者:  Meng, Jian;  Liu, Xiao-Yun;  Ma, Sheng;  Zhang, Hua;  Yu, Song-da
  |  收藏  |  浏览/下载：96/0  |  提交时间：2019/01/08
YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)-mutant resistance in vitro and in vivo 期刊论文  OAI收割
CANCER MEDICINE, 2018, 卷号: 7, 期号: 4, 页码: 1430-1439
作者:  Zhang, Zhang;  Zou, Jian;  Yu, Lei;  Luo, Jinfeng;  Li, Yan
  |  收藏  |  浏览/下载：70/0  |  提交时间：2019/01/08
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer 期刊论文  OAI收割
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 卷号: 110, 页码: 51-61
作者:  Li, Xin;  Yang, Changyong;  Wan, Hong;  Zhang, Ge;  Feng, Jun
  |  收藏  |  浏览/下载：136/0  |  提交时间：2019/01/08
Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC 期刊论文  OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 140, 页码: 510-527
作者:  Chen, Lingfeng;  Fu, Weitao;  Feng, Chen;  Qu, Rong;  Tong, Linjiang
  |  收藏  |  浏览/下载：55/0  |  提交时间：2019/01/08
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl) phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor 期刊论文  OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 131, 页码: 107-125
作者:  Liang, Qianmao;  Chen, Yongfei;  Yu, Kailin;  Chen, Cheng;  Zhang, Shouxiang
  |  收藏  |  浏览/下载：37/0  |  提交时间：2018/07/26